Decrease of Urotensin II activity can impact on the volume status in predialysis chronic kidney disease. (22nd January 2015)

• Record Type: Journal Article
• Authors: Yilmaz, Banu; Yilmaz, Akar; Sari, Funda; Sarikaya, Abdi Metin; Ellidag, Hamit Yasar; Kucukseymen, Selcuk; Ozpelit, Ebru
• Is Part Of: Renal failure. Volume 37:Number 3(2015)
• Page Start: 476
• Page End: 481
• Publication Date: 2015-01-22
• Subjects: Cardio-renal syndrome -- chronic kidney disease -- overhydration -- urotensin II; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.3109/0886022X.2015.1006083
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Urotensin II (U-II) was thought to be one of the mediators of primary renal sodium retention due to effects on renal sodium excretion. For this purpose, the relationship between U-II and overhydration was investigated. A total of 107 patients were enrolled in the study. According to body compositor monitor analysis, fluid overload up to 1.1 L, was considered normohydration. Patients were divided according to hydration status; overhydrate ( n = 42) and normohydrate ( n = 65) were studied in both groups. Pulse waveform velocity propagation for arterial stiffness and blood pressure analysis and echocardiographic left ventricular and left atrial indices were performed with known fluid overload-related parameters. U-II levels were measured by using Human ELISA kit. In overhydrated group, U-II levels were significantly lower. All parameters (blood pressure, arterial stiffness parameters, echocardiographic data, age, gender, diabetes, U-II, hemoglobin) correlated with overhydration, were determined by linear regression model (method = enter), when considered together, U-II was found to be an independent predictor from other conventional overhydration-related parameters. Male sex, left ventricular mass index, left atrial volume index, hemoglobin value were found to be independent predictors for overhydration. Considering the association of low U-II levels with adverse cardiovascular events and its role in sodium retention, we think that low U-II levels can be accepted as a potential therapeutic target in patients with hypervolemic cardio-renal syndrome.